Login to Your Account

Small Win Ahead of First-Line Data

FDA Splits with Panel; Approves Tarceva in NSCLC Maintenance

By Jennifer Boggs

Tuesday, April 20, 2010
The FDA granted approval late Friday for Tarceva (erlotinib) as a maintenance therapy for non-small-cell lung cancer patients, a decision that defied a negative 12-to-1 panel vote last year but is likely to offer only a modest boost to sales of the drug from OSI Pharmaceuticals Inc. and Genentech Inc./Roche AG. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription